The SPEED study: initial clinical evaluation of the Penumbra novel 054 Reperfusion Catheter. (7th January 2013)

• Record Type: Journal Article
• Authors: Frei, Don; Gerber, Johannes; Turk, Aquilla; McPherson, Malia; Heck, Don; Hui, Ferdinand; Joseph, Gregory; Jahan, Reza; Miskolczi, Laszlo; Carpenter, Jeffrey; Grobelny, Thomas; Goddard, Jim; Turner, Raymond D; Huddle, Dan; Bellon, Richard; Chaudry, Imran
• Is Part Of: Journal of neurointerventional surgery. Volume 5(2013)Supplement 1
• Page Start: i74
• Page End: i76
• Publication Date: 2013-01-07
• Subjects: Stroke -- Catheter; Nervous system -- Surgery -- Periodicals; Cerebrovascular disease -- Surgery -- Periodicals; 617.48
• DOI: 10.1136/neurintsurg-2012-010585
• Languages: English
• ISSNs: 1759-8478

Abstract

Abstract : Background and purpose: Revascularization of acute ischemic stroke from a large vessel occlusion continues to be a challenge with current thrombectomy devices. The purpose of the SPEED study was to report the safety and effectiveness of the Penumbra 054 Reperfusion Catheter System in revascularizing large vessel occlusions. Methods: In this retrospective multicenter study, data were collected from patients with angiographic evidence of large vessel occlusion treated with the Penumbra 054 device as the intended primary therapy. Clinical outcome data were collected with 90-day follow-up and the results were compared with those from the Penumbra Pivotal trial. Results: Eighty-seven target vessels in 86 consecutive patients treated with the Penumbra 054 device were included. The Thrombolysis In Myocardial Infarction (TIMI) 2 or 3 revascularization rate was 91% compared with a reported 82% in the Penumbra Pivotal trial. This was accomplished in a median time of 20 min compared with 45 min in the Penumbra Pivotal trial (p<0.0001). Eighteen (21%) patients experienced an intracranial hemorrhage of which 12 (14%) were symptomatic. Good neurologic outcome (modified Rankin scores ≤ 2) at 90-day follow-up was achieved in 34.9% of patients compared with 25% reported in the Penumbra Pivotal trial. All-cause mortality was 25.6%. Conclusions: These results suggest that the Penumbra 054 is a fast, safe and effective revascularization tool for patients experiencing ischemic stroke secondary to large vessel occlusive disease. Improvements in speed and effectiveness of revascularization probably contributed to improved outcomes.